Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company has โน1.426 Trillion in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2024-12-31 | $โน1.434 T | 16.39% |
2023-12-31 | $โน1.232 T | 11.21% |
2022-12-31 | $โน1.107 T | 35.81% |
2021-12-31 | $โน815.74 B | 4.38% |
2020-12-31 | $โน781.51 B | -17.84% |
2019-12-31 | $โน951.22 B | 4.39% |
2018-12-31 | $โน911.20 B | 13.28% |
2017-12-31 | $โน804.39 B | -2.4% |
2016-12-31 | $โน824.19 B | 32.29% |
2015-12-31 | $โน623.00 B | -9.1% |
2014-12-31 | $โน685.36 B | 28.68% |
2013-12-31 | $โน532.59 B | 39.68% |
2012-12-31 | $โน381.28 B | 12.15% |
2011-12-31 | $โน339.98 B | 39.23% |
2010-12-31 | $โน244.18 B | -15.96% |
2009-12-31 | $โน290.55 B | 3.62% |
2008-12-31 | $โน280.40 B | 29.11% |
2007-12-31 | $โน217.19 B | -31.41% |
2006-12-31 | $โน316.66 B | 1.9% |
2005-12-31 | $โน310.76 B | 5.12% |
2004-12-31 | $โน295.63 B | -7.94% |
2003-12-31 | $โน321.13 B | 503.48% |
2002-12-31 | $โน53.21 B | -18.24% |
2001-12-31 | $โน65.08 B |